Impact Factor 4.137 | CiteScore 4.28
More on impact ›
Women’s Cancer is a specialty section of Oncology dedicated to advancing scientific and clinical knowledge of breast and gynecologic cancers. This section seeks to publish articles addressing novel findings, controversies, and innovative hypotheses in the areas of prevention, diagnosis, and treatment of breast and gynecologic malignancies. The primary focus, however, is on the development of a personalized and tailored approach to the prevention and treatment of breast and gynecologic malignancies. These articles will include epidemiologic, basic science, translational and clinical studies. The interactive online forum will allow rapid review and dissemination of these important papers in an open-access format. Specific topics to be covered include:
To be considered for publication, studies must demonstrate the applicability of anticancer modalities on a minimum of two well-authenticated cancer cell lines.
Studies consisting solely of in silico investigation without experimental or in situ validation to support conclusions are not in scope for the Women's Cancer section.
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: coming soon for all published articles
Women's Cancer welcomes submissions of the following article types: Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Women's Cancer, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com